Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. (Nasdaq: ENSC) is a clinical-stage pharmaceutical company focused on developing abuse-deterrent opioid treatments and drug-abuse diagnostics, operating within the specialty pharmaceuticals and healthcare sector. The company completed its SPAC merger and began trading under the ENSC ticker in 2021. On May 15, 2026, the company filed an 8-K with the SEC under accession number 0001493152-26-023810, signaling a reportable corporate event. Ensysce remains an active reporting company following its de-SPAC transition, continuing to pursue regulatory milestones for its proprietary abuse-deterrent drug platform. For full filing history, transaction details, and real-time SPAC data on ENSC and hundreds of other deals, sign up for SpacDesk at spacdesk.com.